Inclusion Criteria:

- Histological proven prostate cancer, locally advanced or metastatic and scheduled to
receive hormonal deprivation therapy

- Life expectancy of more than 9 months

- Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site
within the previous 6 months

Exclusion Criteria:

- Has a history of hypersensitivity to the Investigational Medicinal Product or drugs
with a similar chemical structure

- Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen
within the last year preceding the study

- Concomitant anti-coagulation treatment

- Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy
during the course of this study

- Patient with known spinal medullar compression